Cited by 943Autism Spectrum Disorder ResearchGenetics and Neurodevelopmental DisordersGenomics and Rare Diseases

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; none of the 8 sources its claims cite is checked for support yet.

SFARI Gene 2.0: a community-driven knowledgebase for the autism spectrum disorders (ASDs)

Open access
Abrahams, Brett S, Arking, Dan E, Campbell, Daniel B, Mefford, Heather C, Morrow, Eric M, Weiss, Lauren A, Menashe, Idan, Wadkins, Tim, Banerjee-Basu, Sharmila, Packer, Alan·2013·Molecular Autism

Abstract

New technologies enabling genome-wide interrogation have led to a large and rapidly growing number of autism spectrum disorder (ASD) candidate genes. Although encouraging, the volume and complexity of these data make it challenging for scientists, particularly non-geneticists, to comprehensively evaluate available evidence for individual genes. Described here is the Gene Scoring module within SFARI Gene 2.0 ( https://gene.sfari.org/autdb/GS_Home.do ), a platform developed to enable systematic community driven assessment of genetic evidence for individual genes with regard to ASD.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

SFARI Gene 2.0 introduces a community-driven Gene Scoring module that systematically scores human genetic evidence for ASD candidate genes. In an initial 196-gene set, 58% fell into “Minimal Evidence,” and publication attention was only weakly related to evidence category.

Key findings

  • Of 196 scored genes, 114 (58.2%) were assigned “Minimal Evidence” (category 4); no genes were placed in “High confidence” (category 1), while 5 (2.6%) were “Strong candidate” and 17 (8.7%) “Suggestive.”
  • Publication attention was skewed: among syndromic genes discovered more than four years earlier (n = 17), two genes accounted for almost 50% of ASD-associated publications, while the eight least attended genes in that group collectively accounted for 8.4%.
  • Almost half of genes with no or modest support (categories 4/5/6) had more ASD-associated publications than genes with more evidence (categories S/2/3); Table 1 shows syndromic genes had 714 observed versus 160 expected papers (4.4x), while minimal evidence genes had 360 observed versus 834 expected (0.4x).
  • The resource includes explicitly defined scoring criteria, downloadable data, community score additions/proposals, and staff/advisory board oversight with versioning.

Methods

  • Criteria were developed from a human genetics perspective to quantify evidence for ASD involvement, guided by three principles: use genetic variation in human cohorts, start with no assumptions about individual genes, and make active community involvement central.
  • An initial set of 196 genes was scored and annotated in a gene-centric web interface; users with a SFARI login can add scores alongside curated calls, propose new genes, and suggest modifications to scoring criteria, with oversight by staff curators and the SFARI Gene Advisory Board.
  • Attention analysis used manually curated publication counts containing “(autism OR autistic)” in the title or abstract; Figure 1 used the PubMed query “(autism OR autistic) AND (‘Gene symbol’)” in the title or abstract, and Table 1 compared observed papers to expected papers based on total observed papers across all categories (n = 1,434).

Limitations

  • Stated: the scoring system is “not entirely immune to bias”; scores are not static and will change in the face of new data.
  • Evident: the analysis covers only an initial set of 196 genes, and publication counts are used as a proxy for scientific attention; the paper does not report external validation of the scoring categories.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/2040-2392-4-36

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Weak relationship between strength of ASD-related genetic evidence and the resulting number of scientific publications. Consistent with a disconnect between attention from the research community and evidence in support of individual genes, the number of publications for individual genes is highly variable and only weakly related to gene category. Publication numbers for each gene were obtained via Pubmed, extracting publications containing the query: "(autism OR autistic) AND ('Gene symbol')" in the title or abstract to obtain a count for each scored gene. To minimize false positives, results were manually curated. Publication number was then plotted as a function of both gene category (colors) and years post publication. ASD, autism spectrum disorder.
Figure 1 Weak relationship between strength of ASD-related genetic evidence and the resulting number of scientific publications. Consistent with a disconnect between attention from the research community and evidence in support of individual genes, the number of publications for individual genes is highly variable and only weakly related to gene category. Publication numbers for each gene were obtained via Pubmed, extracting publications containing the query: "(autism OR autistic) AND ('Gene symbol')" in the title or abstract to obtain a count for each scored gene. To minimize false positives, results were manually curated. Publication number was then plotted as a function of both gene category (colors) and years post publication. ASD, autism spectrum disorder.CC BY · PubMed Central

Verification

Claims the paper makes

7 Own interpretation · 6 Own result · 3 Own method · 2 No basis given · 1 Not checked yet

Verify all 8 references — free account
  • It may state two separate claims as one. 8
  • Probably not a substantial claim. 4
10 of 10
  • The paper relies on this without support.

    Downstream work involves considerable resources.

    “Given that downstream work involves considerable resources, a portal and framework enabling systematic assessments of all available evidence holds great value.”
  • The paper relies on this without support.

    The initial set of 196 scored genes is representative of autism-candidate genes proposed to date.

    “Using these newly developed criteria, we scored an initial set of 196 genes.”
    “these data suggest that there exists only modest support for the majority of autism-candidate genes proposed to date.”
  • The paper relies on this without support.

    The number of manually curated publications containing “(autism OR autistic)” in the title or abstract is a valid measure of attention from the scientific community.

    “We then looked at the relationship between category placement and attention from the field, as defined by the number of manually curated publications containing “(autism OR autistic)” in the title or abstract.”
  • The paper relies on this without support.

    The scoring categories accurately reflect the strength of genetic evidence for ASD involvement.

    “Using a human genetics perspective, we developed a set of criteria to quantify evidence for involvement in the ASDs.”
4 of 4

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 9 references

Cited by

Sorted by citations

See all 943

Metadata

Authors
Abrahams, B. S., Arking, D. E., Campbell, D. B., Mefford, H. C., Morrow, E. M., Weiss, L. A., Menashe, I., Wadkins, T., Banerjee-Basu, S., & Packer, A.
Affiliations
  • Albert Einstein College of Medicine (US)
  • Johns Hopkins University (US)
  • University of Southern California (US)
  • University of Washington (US)
  • Brown University (US)
  • University of California, San Francisco (US)
  • Ben-Gurion University of the Negev (IL)
  • MindSpec (US)
  • Simons Foundation (US)
Corresponding author
Packer, Alan
Venue
Molecular Autism
Published
2013-10-03
Volume
4
Issue
1
Pages
36-36
ISSN
2040-2392 (ISSN-L)
OpenAlex
W2168950294
Cited by
873
References
9
Citations by year
2026: 103 · 2025: 115 · 2024: 79 · 2023: 94 · 2022: 110 · 2021: 95 · 2020: 89 · 2019: 60 · 2018: 46 · 2017: 31 · 2016: 26 · 2015: 12 · 2014: 10 · 2013: 1
FWCI
8.92
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Molecular Autism (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Simons Foundation
  • Simons Foundation Autism Research Initiative
  • National Institute of Mental Health (R01MH100027)
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
Keywords
autism spectrum disorder, candidate genes, autism genetics, evidence evaluation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review